n-methyl-3,4-methylenedioxyamphetamine has been researched along with Behavior Disorders in 77 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The classical psychedelic drugs LSD and psilocybin and the entactogen MDMA are showing promise as tools to assist psychotherapy for a wide range of mental disorders, with multiple pilot studies demonstrating their safety and efficacy." | 4.98 | The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant. ( Sessa, B, 2018) |
| "The growing prevalence of mental illness has been associated with significant social and economic costs." | 2.66 | The emerging role of psilocybin and MDMA in the treatment of mental illness. ( Cha, DS; Chen-Li, D; El-Halabi, S; Gill, B; Gill, H; Ho, R; Lee, Y; Lipsitz, O; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD, 2020) |
| "There is a higher frequency of both psychiatric illness and cognitive impairment among ecstasy users." | 2.43 | [Psychiatric and cognitive long-term effects of ecstasy]. ( Bachs, L; Bramness, JG; Høiseth, G; Løvåsdal, Ø; Titze, TK, 2006) |
| " For future research, challenge studies in animals using dosing regimens adapted to human consumption patterns are needed." | 2.42 | The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). ( Freudenmann, RW; Spitzer, M, 2004) |
| "Illicit drug abusers in a Drug Abstention and Treatment Center were recruited to complete the questionnaires and their data were compared with an age-matched control." | 1.35 | Sexual dysfunction in men who abuse illicit drugs: a preliminary report. ( Bang-Ping, J, 2009) |
| " Problematic ecstasy users reported significantly higher levels of ecstasy use, including lifetime consumption, average dosage and binge consumption compared to non-problematic ecstasy users." | 1.33 | Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors. ( Parrott, AC; Soar, K; Turner, JJ, 2006) |
| " Longer-term, larger dosage (acute or cumulative) MDMA consumers were found to be at high risk of developing psychopathological disturbances." | 1.30 | MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. ( Bricolo, R; Di Furia, L; Forza, G; Minicuci, N; Schifano, F, 1998) |
| " Side effects, insight gained, pleasure, and intensity of the MDMA experience were evaluated as were the influence of set and setting at the time the MDMA was taken and the dosage utilized." | 1.28 | Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. ( Bravo, GL; Grob, CS; Liester, MB; Walsh, RN, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.60) | 18.7374 |
| 1990's | 16 (20.78) | 18.2507 |
| 2000's | 32 (41.56) | 29.6817 |
| 2010's | 17 (22.08) | 24.3611 |
| 2020's | 10 (12.99) | 2.80 |
| Authors | Studies |
|---|---|
| Reardon, S | 1 |
| Kisely, S | 1 |
| Nutt, D | 2 |
| Reiff, CM | 1 |
| Richman, EE | 1 |
| Nemeroff, CB | 1 |
| Carpenter, LL | 1 |
| Widge, AS | 1 |
| Rodriguez, CI | 1 |
| Kalin, NH | 1 |
| McDonald, WM | 1 |
| Greif, A | 1 |
| Šurkala, M | 1 |
| Gill, H | 1 |
| Gill, B | 1 |
| Chen-Li, D | 1 |
| El-Halabi, S | 1 |
| Rodrigues, NB | 1 |
| Cha, DS | 1 |
| Lipsitz, O | 1 |
| Lee, Y | 1 |
| Rosenblat, JD | 1 |
| Majeed, A | 1 |
| Mansur, RB | 1 |
| Nasri, F | 1 |
| Ho, R | 1 |
| McIntyre, RS | 1 |
| De Gregorio, D | 1 |
| Aguilar-Valles, A | 1 |
| Preller, KH | 1 |
| Heifets, BD | 2 |
| Hibicke, M | 1 |
| Mitchell, J | 1 |
| Gobbi, G | 1 |
| de Wit, H | 2 |
| Bershad, AK | 1 |
| Grob, C | 2 |
| Hosanagar, A | 2 |
| Cusimano, J | 2 |
| Radhakrishnan, R | 2 |
| Davey, CG | 1 |
| Wagner, D | 2 |
| Sauder, T | 1 |
| Koester, P | 2 |
| Gouzoulis-Mayfrank, E | 5 |
| Daumann, J | 4 |
| Majić, T | 1 |
| Jungaberle, H | 1 |
| Schmidt, TT | 1 |
| Zeuch, A | 1 |
| Hermle, L | 2 |
| Gallinat, J | 1 |
| Sessa, B | 2 |
| Feduccia, AA | 1 |
| Holland, J | 1 |
| Mithoefer, MC | 2 |
| Pitts, EG | 1 |
| Curry, DW | 1 |
| Hampshire, KN | 1 |
| Young, MB | 1 |
| Howell, LL | 1 |
| Curran, HV | 2 |
| Bedi, G | 1 |
| Malenka, RC | 1 |
| Dobry, Y | 1 |
| Rice, T | 1 |
| Sher, L | 1 |
| Becker, B | 1 |
| Hellmich, M | 1 |
| Beaudoin-Gobert, M | 1 |
| Epinat, J | 1 |
| Météreau, E | 1 |
| Duperrier, S | 1 |
| Neumane, S | 1 |
| Ballanger, B | 1 |
| Lavenne, F | 1 |
| Liger, F | 1 |
| Tourvielle, C | 1 |
| Bonnefoi, F | 1 |
| Costes, N | 1 |
| Bars, DL | 1 |
| Broussolle, E | 1 |
| Thobois, S | 1 |
| Tremblay, L | 1 |
| Sgambato-Faure, V | 1 |
| Grob, CS | 3 |
| Brewerton, TD | 1 |
| Keyes, KM | 1 |
| Martins, SS | 2 |
| Hasin, DS | 1 |
| Soar, K | 2 |
| Parrott, A | 1 |
| Turner, J | 1 |
| Wu, ZH | 1 |
| Baillargeon, JG | 1 |
| Berenson, AB | 1 |
| Holzer, CE | 1 |
| Rogers, G | 1 |
| Elston, J | 1 |
| Garside, R | 1 |
| Roome, C | 1 |
| Taylor, R | 1 |
| Younger, P | 1 |
| Zawada, A | 1 |
| Somerville, M | 1 |
| Krebs, TS | 1 |
| Johansen, PØ | 1 |
| Jerome, L | 1 |
| Halpern, JH | 1 |
| Argo, V | 1 |
| Brillant, E | 1 |
| Fulgencio, JP | 1 |
| Bonnet, F | 1 |
| Naito, H | 1 |
| George, AM | 1 |
| Windsor, TD | 1 |
| Rodgers, B | 1 |
| Scott, RM | 1 |
| Hides, L | 1 |
| Allen, JS | 1 |
| Lubman, DI | 1 |
| Cole, JC | 1 |
| Sumnall, HR | 1 |
| Wagstaff, GF | 1 |
| Lieb, R | 1 |
| Schuetz, CG | 1 |
| Pfister, H | 1 |
| von Sydow, K | 1 |
| Wittchen, H | 1 |
| Saarijärvi, S | 1 |
| Lopperi, M | 1 |
| Bynum, B | 1 |
| Simantov, R | 1 |
| Hensen, G | 1 |
| Thimm, B | 1 |
| Rezk, M | 1 |
| Till, B | 1 |
| Verheyden, SL | 1 |
| Maidment, R | 1 |
| Freudenmann, RW | 1 |
| Spitzer, M | 2 |
| Thomasius, R | 1 |
| Petersen, KU | 1 |
| Zapletalova, P | 1 |
| Wartberg, L | 1 |
| Zeichner, D | 1 |
| Schmoldt, A | 1 |
| Herning, RI | 1 |
| Better, W | 1 |
| Tate, K | 1 |
| Cadet, JL | 1 |
| Høiseth, G | 1 |
| Løvåsdal, Ø | 1 |
| Titze, TK | 1 |
| Bramness, JG | 1 |
| Bachs, L | 1 |
| Turner, JJ | 2 |
| Parrott, AC | 4 |
| Mazzotti, G | 1 |
| Chilcoat, HD | 1 |
| Guillot, CR | 1 |
| Berman, ME | 1 |
| Alati, R | 1 |
| Kinner, SA | 1 |
| Hayatbakhsh, MR | 1 |
| Mamun, AA | 1 |
| Najman, JM | 1 |
| Williams, GM | 1 |
| Yen, CF | 1 |
| Hsu, SY | 1 |
| Karlsen, SN | 1 |
| Spigset, O | 1 |
| Slørdal, L | 1 |
| Bang-Ping, J | 1 |
| Nielsen, JC | 1 |
| Nicholson, K | 1 |
| Pitzner-Jørgensen, BL | 1 |
| Undén, M | 1 |
| Allen, RP | 1 |
| McCann, UD | 2 |
| Ricaurte, GA | 2 |
| Series, H | 1 |
| Lindefors, N | 1 |
| Slate, SO | 1 |
| Cohen, RS | 1 |
| Cocores, J | 1 |
| Gillman, PK | 1 |
| Rees, C | 1 |
| Lehane, M | 1 |
| Schifano, F | 1 |
| Di Furia, L | 1 |
| Forza, G | 1 |
| Minicuci, N | 1 |
| Bricolo, R | 1 |
| Morgan, JF | 1 |
| Marston, HM | 1 |
| Reid, ME | 1 |
| Lawrence, JA | 1 |
| Olverman, HJ | 1 |
| Butcher, SP | 1 |
| Scearce-Levie, K | 1 |
| Chen, JP | 1 |
| Gardner, E | 1 |
| Hen, R | 1 |
| Liechti, ME | 1 |
| Vollenweider, FX | 1 |
| Kalant, H | 1 |
| Fox, HC | 1 |
| Milani, RM | 1 |
| Parmar, R | 1 |
| Turner, JD | 1 |
| Liester, MB | 2 |
| Bravo, GL | 2 |
| Walsh, RN | 2 |
| Greer, G | 1 |
| Bravo, G | 1 |
| Walsh, R | 1 |
| Whitaker-Azmitia, PM | 1 |
| Grinspoon, L | 1 |
| Bakalar, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MDMA-Assisted Therapy 6 to 12 Months After Childbirth for People With Co-occurring Opioid Use and Post Traumatic Stress Disorders[NCT05219175] | Phase 2 | 15 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| The Effects of MDMA on Prefrontal and Amygdala Activation in Posttraumatic Stress Disorder[NCT03752918] | Phase 1 | 20 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
27 reviews available for n-methyl-3,4-methylenedioxyamphetamine and Behavior Disorders
| Article | Year |
|---|---|
Psychedelic drugs-a new era in
psychiatry?
.
Topics: Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Mental Disorders; N-Methyl-3,4-methylen | 2019 |
Psychedelics and Psychedelic-Assisted Psychotherapy.
Topics: Evidence-Based Practice; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; N-Meth | 2020 |
Compassionate use of psychedelics.
Topics: Chronic Disease; Compassionate Use Trials; Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-met | 2020 |
The emerging role of psilocybin and MDMA in the treatment of mental illness.
Topics: Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin | 2020 |
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
Topics: Animals; Brain; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Mental Disorders; Menta | 2021 |
Challenges in translational research: MDMA in the laboratory versus therapeutic settings.
Topics: Affect; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Translational Research, Bi | 2022 |
Therapeutic Potential of Psychedelics in the Treatment of Psychiatric Disorders, Part 1: Psychopharmacology and Neurobiological Effects.
Topics: Banisteriopsis; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; N-Methyl-3,4-me | 2021 |
Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2: Review of the Evidence.
Topics: Banisteriopsis; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; N-Methyl-3,4-me | 2021 |
[Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
Topics: Combined Modality Therapy; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; N-Me | 2017 |
The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant.
Topics: Animals; Data Collection; Emotions; Forecasting; Hallucinogens; Humans; Mental Disorders; N-Methyl-3 | 2018 |
Progress and promise for the MDMA drug development program.
Topics: Affect; Animals; Brain; Clinical Trials, Phase II as Topic; Drug Development; Fear; Hallucinogens; H | 2018 |
(±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.
Topics: Animals; Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Stereoisom | 2018 |
Ecstasy use and serotonin syndrome: a neglected danger to adolescents and young adults prescribed selective serotonin reuptake inhibitors.
Topics: Adolescent; Drug Interactions; Humans; Inappropriate Prescribing; Mental Disorders; N-Methyl-3,4-met | 2013 |
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.
Topics: Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychopharmacology; Ps | 2016 |
The harmful health effects of recreational ecstasy: a systematic review of observational evidence.
Topics: Amphetamine-Related Disorders; Cognition; Databases, Bibliographic; Hallucinogens; Humans; Illicit D | 2009 |
[Entactogen and designer drugs (2)].
Topics: Animals; Central Nervous System Stimulants; Designer Drugs; Drug Interactions; Humans; Mental Disord | 2010 |
[Effects of ecstasy on the body].
Topics: Brain; Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Serotonin; S | 2003 |
Multiple molecular and neuropharmacological effects of MDMA (Ecstasy).
Topics: Animals; Behavior; Cells, Cultured; Gene Expression; Hallucinogens; Humans; Mental Disorders; Mice; | 2004 |
The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA).
Topics: 3,4-Methylenedioxyamphetamine; Animals; Drug Administration Schedule; Drug Interactions; Europe; Hal | 2004 |
Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
Topics: Animals; Brain Diseases; Cognition Disorders; Hallucinogens; Humans; Memory Disorders; Mental Disord | 2006 |
[Psychiatric and cognitive long-term effects of ecstasy].
Topics: Animals; Brain; Cognition Disorders; Cross-Sectional Studies; Hallucinogens; Humans; Longitudinal St | 2006 |
The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review.
Topics: Central Nervous System Stimulants; Hallucinogens; Humans; Mental Disorders; Models, Biological; N-Me | 2007 |
The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.
Topics: Animals; Cognition Disorders; Dose-Response Relationship, Drug; Half-Life; Hallucinogens; Humans; Il | 2008 |
[Abuse of Ecstasy (3,4-methylenedioxymethamphetamine). Pharmacological, neuropsychiatric and behavioral aspects].
Topics: Brain Diseases; Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Sub | 1995 |
[Ecstasy--effects and toxicity. Distinct risks but uncertain long-term hazards].
Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain; Humans; Immunohistochemistry; Mental Disorders; N-Met | 1993 |
Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy').
Topics: Animals; Brain; Hallucinogens; Heart; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetami | 1996 |
The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.
Topics: Amphetamines; Brain; Cardiovascular System; Humans; Liver; Mental Disorders; N-Methyl-3,4-methylened | 2001 |
5 trials available for n-methyl-3,4-methylenedioxyamphetamine and Behavior Disorders
| Article | Year |
|---|---|
Neuropsychiatric alterations in MDMA users: preliminary findings.
Topics: Adult; Cerebrovascular Circulation; Electroencephalography; Female; Hallucinogens; Humans; Male; Mar | 2005 |
[Hallucinogen induced psychic disorders. Subjective experiences, psychopathology and differential diagnosis].
Topics: Adolescent; Adult; Comorbidity; Female; Hallucinogens; Humans; Male; Mental Disorders; Mescaline; Mi | 1996 |
The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers.
Topics: Adult; Animals; Blood Pressure; Body Temperature; Citalopram; Cross-Over Studies; Dopamine; Double-B | 2000 |
Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug.
Topics: Adult; Cognition Disorders; Female; Hallucinogens; Humans; Male; Memory, Short-Term; Mental Disorder | 2001 |
Second thoughts on 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity.
Topics: 3,4-Methylenedioxyamphetamine; Amphetamines; Animals; Clinical Trials as Topic; Designer Drugs; Huma | 1990 |
45 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Behavior Disorders
| Article | Year |
|---|---|
US could soon approve MDMA therapy - opening an era of psychedelic medicine.
Topics: Drug Approval; Hallucinogens; Humans; Medicine; Mental Disorders; N-Methyl-3,4-methylenedioxyampheta | 2023 |
The down-scheduling of MDMA and psilocybin(e): Too fast and too soon.
Topics: Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin | 2023 |
Out of the night-time and into the day: Ketamine and MDMA as therapies for mental disorders.
Topics: Hallucinogens; Humans; Ketamine; Mental Disorders; Methamphetamine; N-Methyl-3,4-methylenedioxyamphe | 2021 |
A Longitudinal Study of Self-Reported Psychopathology in Beginning Ecstasy and Amphetamine Users: A Third Follow-up Evaluation.
Topics: Adolescent; Adult; Amphetamine; Amphetamine-Related Disorders; Female; Follow-Up Studies; Hallucinog | 2017 |
Psychedelics and related drugs: therapeutic possibilities, mechanisms and regulation.
Topics: Animals; Brain; Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Str | 2018 |
3,4-Methylenedioxymethamphetamine as a Psychiatric Treatment.
Topics: Clinical Trials, Phase III as Topic; Combined Modality Therapy; Drug Approval; Humans; Mental Disord | 2018 |
Disruptive Psychopharmacology.
Topics: Consciousness; Humans; Ketamine; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybi | 2019 |
End the drug war's research bans.
Topics: Humans; Legislation, Drug; Lysergic Acid Diethylamide; Medical Marijuana; Mental Disorders; N-Methyl | 2014 |
A longitudinal study of self-reported psychopathology in early ecstasy and amphetamine users.
Topics: Adolescent; Adult; Amphetamine-Related Disorders; Cohort Studies; Dextroamphetamine; Female; Humans; | 2015 |
Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate.
Topics: Aniline Compounds; Animals; Antiparkinson Agents; Brain; Brain Mapping; Chlorocebus aethiops; Diseas | 2015 |
Past 12-month and lifetime comorbidity and poly-drug use of ecstasy users among young adults in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
Topics: Adolescent; Adult; Age Factors; Alcoholism; Amphetamine-Related Disorders; Comorbidity; Diagnosis, D | 2008 |
Attributions for psychobiological changes in ecstasy/MDMA and other polydrug users.
Topics: Adult; Attitude; Drug Users; Female; Humans; Illicit Drugs; Life Change Events; Male; Mental Disorde | 2009 |
Self-reported psychopathology among young, low-income, female ecstasy users.
Topics: Academic Medical Centers; Adolescent; Adult; Ambulatory Care Facilities; Analysis of Variance; Cross | 2008 |
Importance of psychiatric confounding in non-randomized studies of heavy ecstasy users.
Topics: Alcohol Drinking; Alcoholism; Amphetamine-Related Disorders; Bias; Cognition Disorders; Comorbidity; | 2009 |
[A young man' spontaneous pneumomediastinum].
Topics: Hallucinations; Hallucinogens; Humans; Male; Mediastinal Emphysema; Mental Disorders; N-Methyl-3,4-m | 2009 |
Are ecstasy users biased toward endorsing somatic mental health symptoms? Results from a general community sample.
Topics: Adult; Amphetamine-Related Disorders; Australia; Female; Humans; Longitudinal Studies; Male; Mental | 2011 |
Subacute effects of ecstasy on mood: an exploration of associated risk factors.
Topics: Adult; Affect; Anxiety; Depression; Female; Follow-Up Studies; Humans; Male; Mental Disorders; N-Met | 2013 |
Methodological problems with ecstasy and the SCL-90.
Topics: Evaluation Studies as Topic; Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamp | 2002 |
Mental disorders in ecstasy users: a prospective-longitudinal investigation.
Topics: Adolescent; Adult; Causality; Cross-Sectional Studies; Female; Germany; Hallucinogens; Humans; Male; | 2002 |
Ecstasy.
Topics: Emotions; History, 17th Century; History, 19th Century; History, 20th Century; History, Ancient; His | 2003 |
Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation.
Topics: Adult; Cannabis; Cross-Sectional Studies; Drug Interactions; Female; Hallucinogens; Humans; Illicit | 2004 |
Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health.
Topics: Adult; Affect; Aggression; Amphetamine-Related Disorders; Anxiety; Decision Making; Hallucinogens; H | 2003 |
Think harder about ecstasy.
Topics: Animals; Brain; Clinical Trials as Topic; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphe | 2004 |
Can psychedelics have a role in psychiatry once again?
Topics: Hallucinogens; History, 20th Century; Humans; Lysergic Acid Diethylamide; Mental Disorders; Mescalin | 2005 |
Mental disorders in current and former heavy ecstasy (MDMA) users.
Topics: Adult; Amphetamine-Related Disorders; Anxiety Disorders; Cognition Disorders; Cross-Sectional Studie | 2005 |
Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors.
Topics: Adolescent; Adult; Amphetamine-Related Disorders; Anxiety Disorders; Comorbidity; Depressive Disorde | 2006 |
Recent-onset ecstasy use: association with deviant behaviors and psychiatric comorbidity.
Topics: Adolescent; Adult; Child; Data Collection; Diagnosis, Dual (Psychiatry); Female; Humans; Likelihood | 2006 |
MDMA (Ecstasy) use and psychiatric problems.
Topics: Amphetamine-Related Disorders; Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxya | 2007 |
Pathways to ecstasy use in young adults: anxiety, depression or behavioural deviance?
Topics: Adolescent; Adolescent Behavior; Adult; Analysis of Variance; Anxiety; Child; Child Behavior Disorde | 2008 |
Symptoms of ecstasy dependence and correlation with psychopathology in Taiwanese adolescents.
Topics: Adolescent; Adolescent Behavior; Attitude to Health; Comorbidity; Diagnosis, Dual (Psychiatry); Fema | 2007 |
Sexual dysfunction in men who abuse illicit drugs: a preliminary report.
Topics: Adult; Amphetamines; Demography; Erectile Dysfunction; Health Status; Heroin Dependence; Humans; Ill | 2009 |
Persistent effects of (+/- )3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Amphetamines; Electroencephalography; Female; Humans; Male; Me | 1993 |
Neuropsychiatric manifestations following the use of 3,4-methylenedioxymethamphetamine (MDMA: "Ecstasy").
Topics: Adolescent; Brain Diseases; Humans; Male; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; | 1997 |
Ecstasy, serotonin syndrome and the treatment of hyperpyrexia.
Topics: Drug Overdose; Fever; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Serotonin; S | 1997 |
Return to Ecstasy.
Topics: Adolescent; Follow-Up Studies; Heroin Dependence; Humans; Mental Disorders; Mental Health; N-Methyl- | 1997 |
MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients.
Topics: Adult; Dose-Response Relationship, Drug; Female; Hallucinogens; Humans; Illicit Drugs; Male; Mental | 1998 |
Toxic effect of MDMA on brain serotonin neurons.
Topics: Binding Sites; Brain; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Serotonin; S | 1999 |
Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat.
Topics: Animals; Behavior, Animal; Biogenic Monoamines; Chromatography, High Pressure Liquid; Citalopram; Ki | 1999 |
5-HT receptor knockout mice: pharmacological tools or models of psychiatric disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aggression; Animals; Behavior, Animal; Cocaine; Disease Models, Anim | 1999 |
Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems.
Topics: Adolescent; Adult; Analysis of Variance; Female; Humans; Illicit Drugs; Italy; Male; Mental Disorder | 2001 |
Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use.
Topics: 3,4-Methylenedioxyamphetamine; Adult; Combined Modality Therapy; Designer Drugs; Emotions; Female; H | 1992 |
The MDMA-neurotoxicity controversy: implications for clinical research with novel psychoactive drugs.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Combined Modality Therapy; Designer Drugs; Humans; Mental Di | 1992 |
Ecstasy and the dance of death.
Topics: 3,4-Methylenedioxyamphetamine; Designer Drugs; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxy | 1992 |
Depression to ecstasy. The Neuropharmacology of Serotonin sponsored by the New York Academy of Sciences, New York, NY, USA, July 10-13, 1989.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain Mapping; Depression; Humans; Mental Disorders; Migrain | 1989 |
Can drugs be used to enhance the psychotherapeutic process?
Topics: 3,4-Methylenedioxyamphetamine; Adult; Awareness; Female; Hallucinogens; Humans; Lysergic Acid Diethy | 1986 |